Physician profile
Robert D Bennett
NPI 1023456290
$1,076.44
in general payments reported to CMS, 2019-2025
10 companies · $268 in 2025
The $268 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $323 · 2020: $41.32 · 2021: $28.69 · 2022: $50.72 · 2023: $68.80 · 2024: $296 · 2025: $268.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $633.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $632.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $439.25 | 2023-2025 | Repatha, Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $323.32 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $103.37 | 2019-2024 | Breztri, Airsupra |
| Abbvie INC. | $61.97 | 2024-2025 | |
| Novo Nordisk INC | $47.60 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $39.49 | 2020-2022 | |
| Pfizer INC. | $31.92 | 2025 | |
| Abbott Laboratories | $16.02 | 2023 | Freestyle Libre 3 |
| Dexcom, INC. | $13.50 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Bennett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.